PHLPP2 is a pseudophosphatase that lost activity in the metazoan ancestor
Tarik Husremovic,Katharina M Siess,Sumire Antonioli,Lucas Piech,Vanessa Meier,Irina Grishkovskaya,Nikoleta Kircheva,Silvia E Angelova,Andreas Brandstaetter,Jiri Veis,Fran Miocic-Stosic,Dorothea Anrather,Markus Hartl,Linda Truebestein,Bojan Zagrovic,Stephan Hann,Christoph Bock,Egon Ogris,Todor Dudev,Nicholas A.T. Irwin,David Haselbach,Thomas A Leonard
DOI: https://doi.org/10.1101/2024.12.03.625870
2024-12-04
Abstract:The phosphoinositide 3-kinase (PI3K) pathway is a major regulator of cell and organismal growth. Consequently, hyperactivation of PI3K and its downstream effector kinase, Akt, is observed in many human cancers. PH domain leucine-rich repeat-containing protein phosphatases (PHLPP), two paralogous members of the metal-dependent protein phosphatase family, have been reported as negative regulators of Akt signaling and, therefore, tumor suppressors. However, the stoichiometry and identity of the bound metal ion(s), mechanism of action, and enzymatic specificity of these proteins are not known. Seeking to fill these gaps in our understanding of PHLPP biology, we unexpectedly discovered that PHLPP2 has no catalytic activity against the regulatory phosphorylation sites of Akt, nor the generic substrate para-nitrophenylphosphate. Instead, we found that PHLPP2 is a pseudophosphatase with a single zinc ion bound in its catalytic center. Furthermore, we found that current cancer genomics data do not support the proposed role of PHLPP1 or PHLPP2 as tumor suppressors. Phylogenetic analyses revealed an ancestral phosphatase that arose more than 1 Mya, but that lost activity at the base of the metazoan lineage. In summary, our results provide a molecular explanation for the inconclusive results that have hampered research on PHLPP and argue for a new focus on non-catalytic roles of PHLPP1 and PHLPP2.
Biochemistry